Nuvalent Inc.

NASDAQ: NUVL · Real-Time Price · USD
77.08
2.47 (3.31%)
At close: Jun 02, 2025, 3:59 PM
77.18
0.13%
After-hours: Jun 02, 2025, 04:55 PM EDT

Company Description

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer.

Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial.

The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Nuvalent Inc.
Nuvalent Inc. logo
Country United States
IPO Date Jul 29, 2021
Industry Biotechnology
Sector Healthcare
Employees 162
CEO Dr. James R. Porter Ph.D.

Contact Details

Address:
One Broadway
Cambridge, Massachusetts
United States
Website https://www.nuvalent.com

Stock Details

Ticker Symbol NUVL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001861560
CUSIP Number 670703107
ISIN Number US6707031075
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. James R. Porter Ph.D. Chief Executive Officer, President & Director
Alexandra Balcom CPA, M.B.A. Chief Financial Officer & Treasurer
Deborah Ann Miller J.D., Ph.D. Chief Legal Officer & Secretary
Darlene Noci Chief Development Officer
Dr. Benjamin Lane Ph.D. Senior Vice President of Technical Operations
Dr. Christopher D. Turner M.D. Chief Medical Officer
Dr. Henry Pelish Ph.D. Chief Scientific Officer
John Soglia Ph.D. Senior Vice President of Translational Development
Matthew Metivier M.B.A. Senior Vice President of Human Resources
Prof. Matthew D. Shair Ph.D. Founder, Head of Scientific Advisory Board & Director

Latest SEC Filings

Date Type Title
May 30, 2025 4 Filing
May 16, 2025 4 Filing
May 08, 2025 10-Q Quarterly Report
May 08, 2025 8-K Current Report
May 01, 2025 4 Filing
Apr 28, 2025 SCHEDULE 13G/A [Amend] Filing
Apr 28, 2025 ARS Filing
Apr 28, 2025 DEFA14A Filing
Apr 28, 2025 DEF 14A Filing
Apr 17, 2025 4 Filing